Hartsough, Edward J.
Weiss, Michele B.
Heilman, Shea A.
Purwin, Timothy J.
Kugel, Curtis H. III
Rosenbaum, Sheera R.
Erkes, Dan A.
Tiago, Manoela
HooKim, Kim
Chervoneva, Inna
Aplin, Andrew E.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA182635, CA196278, CA056036, CA207855)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
National Cancer Center
American Cancer Society (PF-18-096-01-LIB)
Article History
Received: 27 November 2018
Revised: 5 March 2019
Accepted: 7 March 2019
First Online: 25 March 2019
Funding
: This work was supported by the National Cancer Center and National Institutes of Health (NIH) (K99/R00 CA207855) to E.J. Hartsough, and (R01 CA182635, R01 CA196278) to A.E. Aplin, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation to A.E. Aplin. D. A. Erkes is supported by an American Cancer Society—CEO’s Against Cancer—PA Chapter Postdoctoral Fellowship (PF-18-096-01-LIB). The Sidney Kimmel Cancer Center Flow Cytometry, Translational Pathology and Meta-Omics core facilities are supported by NIH/National Cancer Institute Support Grant (P30 CA056036).
: A.E. Aplin reports receiving a commercial research grant from Pfizer Inc. (2013-2017), has ownership interest in patent number 9880150 and has consulted for SpringWorks Therapeutics and Fortress Biotech within the last 3 years. No potential conflicts of interest were disclosed by the other authors.